Pulmonary arterial hypertension: a rare disease that encourages the development of multiple treatments

Bibliography

• Norman P. Orphan drug approvals in Europe since 2001: an analysis by indication. Exp Opin Orphan Drugs 2013;1(2):131-9
   Web of Science ®Google Scholar
• Kirson NY, Birnbaum HG, Ivanova JI, et al. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin 2011;27(9):1763-8
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins I, Beghetti M, et al. “Updated Clinical classification of pulmonary hypertension”. J Am Coll Cardiol 2009;54(1 Suppl):S43-54
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30(1):104-9
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert H, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-537
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94
   PubMed Web of Science ®Google Scholar
• Tuder RM, Stacher E, Robinson J, et al. Pathology of pulmonary hypertension. Clin Chest Med 2013;34(4):639-50
   PubMed Web of Science ®Google Scholar
• Channick R, Preston I, Klinger JR. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Clin Chest Med 2013;34(4):811-24
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Palevsky HI. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. Clin Chest Med 2013;34(4):825-40
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl):5S-12
   Google Scholar
• Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 2011;139:128-37
   PubMed Web of Science ®Google Scholar
• McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013;24:62(25 Suppl):D51-9
   Google Scholar
• United Therapeutics Corp, Cowen and Company 34th Annual Health Care Conference. 2014. Available from: http://files.shareholder.com/downloads/UTHR/2999876736x0x732028/12865ae6-c58a-43ba-a2ac-f5fb72352018/UTHR%20Cowen%202014.pdf
   Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351(14):1425-36
   PubMed Web of Science ®Google Scholar
• Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D60-72
   PubMed Web of Science ®Google Scholar
• Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev 2012;64(3):583-620
   PubMed Web of Science ®Google Scholar
• Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012;21(126):321-7
   PubMedGoogle Scholar
• Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31(4):891-901
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
   PubMed Web of Science ®Google Scholar
• Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther 2012;6:19-28
   PubMed Web of Science ®Google Scholar
• Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142(6):1383-90
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123(4):1293-5
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2010;11(1):127-32
   PubMed Web of Science ®Google Scholar
• Udeoji DU, Schwarz ER. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis 2013;7(1):39-49
   Google Scholar
• Larche NE, Mousa SA. Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Drugs Today (Barc) 2013;49(12):761-8
   Google Scholar
• Steiner MK, Preston IR. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2008;4(5):943-53
   PubMedGoogle Scholar
• Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31(2):407-15
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galiè N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol 2014;172(2):332-9
   PubMed Web of Science ®Google Scholar
• Valerio CJ, Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag 2009;5:607-19
   PubMedGoogle Scholar
• Cohen H, Chahine C, Hui A, Mukherji R. Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm 2004;61(11):1107-19
   Google Scholar
• Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327(3):736-45
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Sidharta PN, Maddrey WC, et al. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf 2014;13(3):391-405
   PubMed Web of Science ®Google Scholar
• Waxman AB. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Vasc Health Risk Manag 2007;3(1):151-7
   PubMedGoogle Scholar
• Croxtall JD, Keam SJ. Ambrisentan. Drugs 2008;68(15):2195-204
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2012;60(1):80-1
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Acute dosing of MK-8892 in participants with pulmonary arterial hypertension (PAH) (MK-8892-003). 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01934647
   Google Scholar
• Kunieda T, Nakanishi N, Matsubara H, et al. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J 2009;50(4):513-29
   PubMedGoogle Scholar
• Skoro-Sajer N, Lang IM. Selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2014;15(3):429-36
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008;32(5):1289-94
   PubMed Web of Science ®Google Scholar
• Parsley EL, Husaini A, Masamune H, et al. Inhaled sodium nitrite: results of multiple ascending dose studies including pharmacodynamic interaction with sildenafil in normal healthy volunteers. Am J Respir Crit Care Med 2012;185:A4800
   Google Scholar
• Parsley EL, Masamune H, Hoye WL, et al. Nebulized inhaled nitrite (AIR001) for pulmonary arterial hypertension: studies to determine safety, pharmacokinetics, and maximum tolerated dose, lack of pharmacodynamic interaction with sildenafil and optimal nebulizer device. Nitric Oxide 2013;31(1):S41-2
   Google Scholar
• MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000;131:161-8
   PubMed Web of Science ®Google Scholar
• Launay JM, Herve P, Peoc’h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129-35
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Al-Hiti H, Vonk-Noordegraaf A, et al. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase IIa study. Am J Respir Crit Care Med 2012;185:A2496
   Google Scholar
• Ventrus Biosciences. Method for treating pulmonary arterial hypertension. US8324247; 2012
   Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127(10):1128-38
   PubMed Web of Science ®Google Scholar
• Waxman AB, Lawler L, Cornett G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med 2008;168(19):2164-6
   PubMed Web of Science ®Google Scholar
• Waxman AB, Lawler L. Cicletanine therapy is well tolerated in patients with advanced pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2009;179:A3353
   Google Scholar
• Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010;56(6):696-708
   PubMed Web of Science ®Google Scholar
• Stacpoole PW. The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine—both or neither? Environ Health Perspect 2011;119(2):155-8
   Google Scholar
• Shenoy V, Ferreira AJ, Qi Y, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182(8):1065-72
   Google Scholar
• Alam SR, Newby DE, Henriksen PA. Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium. Biochem Pharmacol 2012;83:695-704
   PubMed Web of Science ®Google Scholar
• Nickel NP, Wang L, Li CG, et al. The elastase inhibitor Elafin restores endothelial cell homeostasis in pulmonary arterial hypertension and attenuates vascular remodeling in the sugen/hypoxia rat model. Am J Respir Crit Care Med 2013;187:A1031
   Google Scholar
• Buckley MS, Staib RL, Wicks LM. Combination therapy in the management of pulmonary arterial hypertension. Int J Clin Pract Suppl 2013(179):13-23
   Google Scholar